

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

## Death from neglected pituitary adenoma, a case report.

**ABSTRACT:** We present a case of a patient who presented with pituitary macroadenoma complicated with hydrocephalus. He presented late to the referral hospital in a comatose state and died a few hours later. He was a 33-year-old, male who gave a history of highly accelerated symptoms lasting 1 week. Neurosurgical consultation as well as investigations with CT scan or MRI were not availed the patient, which could have been life saving. Autopsy findings were of a pituitary macroadenoma and signs of hydrocephalus and raised intracranial pressure which proved fatal.

**Keywords:** Pituitary, adenoma, hydrocephalus.

### INTRODUCTION

Pituitary adenomas (PA) are intracranial tumours that may result in death(1). Autopsy studies suggest that microadenomas (<10mm) occur in 10 to 20% of the population (2, 3), while macroadenomas >10mm are quite rare(4, 5). PA commonly produce ocular, or endocrine symptoms (6), others symptoms relate to mass effect as well as obstruction to cerebrospinal fluid(CSF) flow. Giant PA  $\geq 4$ cm have been reported(7-10). PA occur mostly in adults, but a case in infancy resulting in sudden death was reported(11). Equally occurrence in paediatric age range as well as adolescents(12,13) are reported. PA account for 10% of intracranial neoplasms, and most these arise from the adenohypophysis, other sites are involved by extension, infiltration or ectopic location(14,15). PA present a challenge to the clinician in determining the clinical significance, appropriate diagnosis, need for treatment and type of therapies/therapies(16). PA may be functional(FA) or non-functional(NFA). Functional adenoma may produce a single hormone such as growth hormone(GH) secreting somatostatinomas, prolactin(PRL)prolactinomas, adrenocorticotrophic hormone(ACTH)corticotrophinomas, thyroid stimulating hormone(TSH) thyrotropinomas (17,18) and other rare hormone products(19) or mixed hormones(20). Clinical presentations may range from acromegaly or gigantism(21), Cushing's syndrome(22), Nelson syndrome, hyperprolactinaemia, and other rare endocrine syndromes. Most cases are sporadic, but some occur as part of multiple endocrine neoplasia1 (23,24), or other inheritable tumour syndromes(25), and may occur with other tumours(26,27).

Mortality in the NFA adenoma is commonly due to hormone deficiency, surgery, and mass effect as they often grow very large before detection(28,29). In one series patient died of circulatory complications, respiratory complications as well as infections(28), and in another series patients suffered occult hydrocephalus, and they died of complications following repeated interventions(30). The common presentation of NFA remain, headaches visual disturbance and the hormonal deficiencies(31). Among the functioning(FA), mortality from vascular disease is the predominant cause of death(28). In ACTH producing adenomas, control of cortisol and growth hormone secretion limits the cardiovascular risk(28). Pituitary apoplexy is a sudden vascular event in a PA that can also be life threatening(32,33), and has been reported to induce severe intracerebral haemorrhage(34,35), and death(36). Cases of hydrocephalus complicating PA were successfully treated through neurosurgical shunt procedures(37,38). In our environment an interplay of sociocultural and adverse economic factors frequently stand in the way of clinical care leading to disastrous consequences for patients. It is common to see patients consult traditional medicine practitioners due to cultural and economic considerations, only to appear orthodox medical care when it is very late.

### CASE REPORT:

We present the case of a 33-year-old man with a history of headache of seven days duration. Blurring of vision of 2 day, seizures which were intermittent and unconsciousness of a day's duration. The headache was of sudden onset, noticed on the right temporal area and later became generalized. Described as the worse headache he has ever suffered. No known aggravating or relieving factor. Pain was said to radiate to the neck. Patient was initially ambulant but later could not undertake normal activities and could not sleep. There was no fever or associated but vomited repeatedly. The vomitus was non projectile, on bilious and comprised of recently ingested feeds.

50 He then developed tonic clonic seizure with an episode lasting 2 minutes, terminating in a cry and urinary  
51 incontinence.

52 Patient lapsed into unconsciousness on the way from the point of first consultation to the referral centre in  
53 the teaching hospital.

54 His past medical history was not contributory.

55 He was not known to indulge in alcohol or tobacco use. There was no previous history of hypertensive or  
56 diabetes mellitus, and had not recently travelled to the meningitis belt of the country.

57 Physical examination revealed a young man gasping for breath, was on oxygen at the time of reception at  
58 the referral hospital.

59 **CNS EXAMINATION:** He was unconscious with a Glasgow coma scale of 3/15 distributed as  
60 spontaneous eye movement(E1), verbal response(V1), motor response(M1).

61 Pupils were 5cm dilated and fixed, non-reactive to light (direct and consensual).

62 The neck was supple, Kernig's and Brudzinski signs were negative.

63 Cranial nerves 11, 111,1V, V11,1X,X were non responsive.

64 Muscle tone was reduced in all the limbs. Muscle power could not be assessed objectively.

65 There was generalized depression in limbs reflexes, both plantar and flexor.

#### 66 **RESPIRATORY SYSTEM:**

67 The respiratory rate RR: was 42 cycles per minute and was gasping. The chest was resonant and breath  
68 sounds were vesicular.

69 **CARDIOVASCULAR SYSTEM:**Pulse rate was 140 bpm,small volume .The apex beat, was at the normal  
70 position, jugular venous pressure was not raised.

71 The blood pressure progressively fell from 120/60 mmHg on admission at 9am to being unrecordable at  
72 12 noon.

73 Examination of the other organ systems did not reveal any significant find.

#### 74 **PRESUMPTIVE DIAGNOSIS:**

75 (1) Subarachnoid haemorrhage secondary to ruptured aneurism.

76 (2) Space occupying lesion (Glioma)

77 Patient was admitted into the intensive care unit under the neurology unit.

#### 78 **INVESTIGATIONS AND RESULTS.**

79 (1) Random blood sugar RBS 12.4mmol/l.

80 (2) Urinalysis was normal.

81 (3) HIV screening was Negative

82 (4) Complete blood count: Total wbc 5x 10/dl, Lymphocytes 47%,Neu.50%,eos.1%

83 Platelets; in normal range.

84 (5) Serum electrolytes: Sodium:130mm/l, Potassium.3.3 mm/l calcium, magnesium and creatinine  
85 were being processed before patients' demise.

86 (6) Skull X ray was ordered but was not done because the patient was very unstable.

87 (7) Cranial CAT scan and MRI were, ordered but were not done before patient passed.

#### 88 **TREATMENT:**

89 (1) 20 % Mannitol 250 ml over 4 hours, every 8 hrs. for 72 hrs.

90 (2) Normal saline 1 litre 8 hourly for 72 hours.

91 (3) Intravenous frusemide 20 litres after each dose of mannitol.

92 (4) Monitoring of vital signs every 30 minutes.

93 (5) Strict monitoring of fluid input and output.


94 **OUTCOME:** Patients died within two hours. Autopsy was ordered for.

#### 95 **AUTOPSY FINDINGS:**

96 Patient was generally well nourished looking, male,1.62m in height and weighing 72kg.The pupil were  
97 dilated and fixed. Other physical examinations carried out were found to be in the normal range.

98 The main autopsy findings were in the central nervous system (CNS) and the bones surrounding the sella  
99 tursica. The brain weighed 1350g, The gyri were flattened bilaterally and the sulci narrowed. There was  
100 bilateral uncal and cerebellar tonsillar grooving. A large pituitary tumour measuring 3.4 x2 x 2 cm was  
101 found completely occluding the 3<sup>rd</sup> ventricle and projecting into the lateral ventricles. The lateral ventricles  
102 were dilated on both sides, the left measuring 12 cm long and 8 cm in the widest portion. The right  
103 measured 12 cm long and 7cm in the widest portion.The bones of the sella tursica were significantly

104 eroded, but the tumour was still covered by the diaphragma sella and the carvenous sinus had not been  
105 eroded into.



106  
107 **Figure 1:** Left cerebral hemisphere showing a pituitary adenoma and markedly enlarged lateral ventricle.  
108

109  
110 A diagnosis of Pituitary adenoma causing Hydrocephalus was made.  
111 The cause of death was concluded to be coning due to hydrocephalus, which in turn was induced by a  
112 pituitary adenoma.

113 **DISCUSSION:**

114 Although the patient history suggested a symptom duration of 1 week, the findings at autopsy suggested  
115 otherwise. It is very likely that the pituitary adenoma had been for a while inducing symptoms which were  
116 not heeded to until it became too late. Adenomas that grow very large tend to be the non-functional  
117 types(6,28) in most cases, although one series in the United States reported 5 giant prolactinomas in  
118 (7).Patients with the functional adenomas normally seek medical attention quicker because of the  
119 endocrine symptoms they induce (16).Our index patient had no hormonal assay or immunohistochemistry  
120 to determine if the PA was functional or not. There was however raised random blood sugar which may  
121 suggest hypercortisolism, or even raised thyroid hormones. It is also important to state that the types of  
122 resources needed to save this patient are currently not in our centre. Early presentation would still have  
123 been beneficial to the patient because our hospital operates a robust referral system which would have  
124 been activated to save the patient's life. The lessons to learn in this case is the need for early hospital  
125 consultation when seemingly ordinary symptoms such as persistent headaches, blurring of vision are  
126 encountered. In our country the alternative medical practitioners often act as a barrier between patients  
127 and orthodox medical consultations, often with disastrous consequences.

128 **CONCLUSION:**This case highlights the common practise of patents arriving late for hospital  
129 treatment.Although the patient would have still had a tough time accessing the kind of care that will bring  
130 relief in this case.Government should intervene to change the circumstances that will improve patients  
131 welfare

132 **CONSENT:** Patients personal data was anonymised and permission for the use of specimen  
133 photographs was granted by the Department of Pathology, University of Calabar Teaching hospital.

134

135 **ETHICAL APPROVAL:** There were no ethical issues in this case and permission to report this  
136 case was granted by the institutional review board,  
137

## 138 REFERENCES

- 139 1. Wang AR, Gill JR. The Pituitary Gland: An Infrequent but Multifaceted Contributor to Death. *Acad*  
140 *Forensic Pathol.* 2016;6(2):206-16.
- 141 2. Stadnik T, Spruyt D, van Binst A, Luybaert R, d'Haens J, Osteaux M. Pituitary microadenomas:  
142 diagnosis with dynamic serial CT, conventional CT and T1-weighted MR imaging before and after  
143 injection of gadolinium. *Eur J Radiol.* 1994;18(3):191-8.
- 144 3. Scanarini M, Mingrino S, Boscaro M, Sicolo N, Serafini E, Billeci D. Pituitary microadenomas:  
145 surgical results and morphological findings. *Acta Neurochir (Wien).* 1983;69(3-4):231-42.
- 146 4. Molitch ME, Russell EJ. The pituitary "incidentaloma". *Ann Intern Med.* 1990;112(12):925-31.
- 147 5. McNicol AM, Walker E, Farquharson MA, Teasdale GM. Pituitary macroadenomas associated  
148 with hyperprolactinaemia: immunocytochemical and in-situ hybridization studies. *Clin Endocrinol*  
149 *(Oxf).* 1991;35(3):239-44.
- 150 6. Goldstein JE, Sherman JF. Pituitary adenoma. *Optom Clin.* 1993;3(3):101-25.
- 151 7. Madsen H, Borges TM, Knox AJ, Michaelis KA, Xu M, Lillehei KO, et al. Giant pituitary  
152 adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling. *Am J*  
153 *Surg Pathol.* 2011;35(8):1204-13.
- 154 8. Siddiqui AA, Bashir SH. Giant pituitary macroadenoma at the age of 4 months: case report and  
155 review of the literature. *Childs Nerv Syst.* 2006;22(3):290-4.
- 156 9. Goel A, Nadkarni T, Muzumdar D, Desai K, Phalke U, Sharma P. Giant pituitary tumors: a study  
157 based on surgical treatment of 118 cases. *Surg Neurol.* 2004;61(5):436-45; discussion 45-6.
- 158 10. Barrera CM, Ruiz AE, Banks WA. A giant prolactinoma and the effect of chronic bromocriptine  
159 therapy on basal and TRH-stimulated serum prolactin levels. *Horm Res.* 1991;35(3-4):167-9.
- 160 11. Matsuura H, Kitazawa Y, Tanaka M, Morooka K. Pituitary adenoma and unexpected sudden  
161 infant death: a case report. *Med Pediatr Oncol.* 1994;22(4):283-6.
- 162 12. Kanter SL, Mickle JP, Hunter SB, Rhoton AL. Pituitary adenomas in pediatric patients: are they  
163 more invasive? *Pediatr Neurosci.* 1985;12(4-5):202-4.37
- 164 13. Ortiz-Suarez H, Erickson DL. Pituitary adenomas of adolescents. *J Neurosurg.* 1975;43(4):437-9.
- 165 14. Wong K, Raisanen J, Taylor SL, McDermott MW, Wilson CB, Gutin PH. Pituitary adenoma as an  
166 unsuspected clival tumor. *Am J Surg Pathol.* 1995;19(8):900-3.
- 167 15. Platta CS, Mackay C, Welsh JS. Pituitary adenoma: a radiotherapeutic perspective. *Am J Clin*  
168 *Oncol.* 2010;33(4):408-19.
- 169 16. Vance ML. Pituitary adenoma: a clinician's perspective. *Endocr Pract.* 2008;14(6):757-63.
- 170 17. Oruckaptan HH, Senmevsim O, Ozcan OE, Ozgen T. Pituitary adenomas: results of 684  
171 surgically treated patients and review of the literature. *Surg Neurol.* 2000;53(3):211-9.
- 172 18. Linquette M, Herlant M, Fossati P, May JP, Decoux M, Fourlinnie JC. [Pituitary adenoma with  
173 thyrotropic cells with hyperthyroidism]. *Ann Endocrinol (Paris).* 1969;30(6):731-40.
- 174 19. Esiri MM, Adams CB, Burke C, Underdown R. Pituitary adenomas: immunohistology and  
175 ultrastructural analysis of 118 tumors. *Acta Neuropathol.* 1983;62(1-2):1-14.
- 176 20. Oda S, Wada Y, Kondo H, Ishikawa Y, Kadota K. Pituitary adenoma with prolactin and growth  
177 hormone production in a sheep. *J Comp Pathol.* 1997;117(2):171-5.
- 178 21. Zang X, Zhang SY, Zhang SH, Lu YJ, Wang WJ, Yin ZY, et al. Pituitary adenomas with  
179 acromegaly. Light microscopic and electron microscopic study of 60 cases. *Chin Med J (Engl).*  
180 1983;96(9):647-54.
- 181 22. Raffel C, Boggan JE, Eng LF, Davis RL, Wilson CB. Pituitary adenomas in Cushing's disease: do  
182 they arise from the intermediate lobe? *Surg Neurol.* 1988;30(2):125-30.
- 183 23. Dralle H, Altenahr E. Pituitary adenoma, primary parathyroid hyperplasia and papillary (non-  
184 medullary) thyroid carcinoma. A case of multiple endocrine neoplasia (MEN). *Virchows Arch A*  
185 *Pathol Anat Histol.* 1979;381(2):179-87.
- 186 24. Scheithauer BW, Laws ER, Jr., Kovacs K, Horvath E, Randall RV, Carney JA. Pituitary adenomas  
187 of the multiple endocrine neoplasia type I syndrome. *Semin Diagn Pathol.* 1987;4(3):205-11.
- 188 25. Nakajima M, Nakasu Y, Nakasu S, Matsuda M, Handa J. [Pituitary adenoma associated with  
189 neurofibromatosis: case report]. *Nihon Geka Hokan.* 1990;59(3):278-82.

- 190 26. Gokden M, Mrak RE. Pituitary adenoma with craniopharyngioma component. *Hum Pathol.* 2009;40(8):1189-93.  
191  
192 27. Xekouki P, Szarek E, Bullova P, Giubellino A, Quezado M, Mastroyannis SA, et al. Pituitary  
193 adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects  
194 in humans and mice. *J Clin Endocrinol Metab.* 2015;100(5):E710-9.  
195 28. Tampourlou M, Fountas A, Ntali G, Karavitaki N. Mortality in patients with non-functioning  
196 pituitary adenoma. *Pituitary.* 2018;21(2):203-7.  
197 29. Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, et al. Mortality  
198 in patients with pituitary disease. *Endocr Rev.* 2010;31(3):301-42.  
199 30. CROWLEY HASAJN. Hydrocephalus complicating pituitary adenoma. *Journal ofNeurology,*  
200 *Neurosurgery, and Psychiatry* 1973, ;36, :1063-8.  
201 31. Danfeng Zhang JC, Zhenxing Li, Junyu Wang, Kaiwei Han and Lijun Hou Clinical features and  
202 management of nonfunctioning giant pituitary adenomas causing hydrocephalus. *Oncotarget,* .  
203 2018,; Vol. 9, ( . 20):15409-17.  
204 32. Yoshino M, Sekine Y, Koh E, Hata A, Hashimoto N. Pituitary apoplexy after surgical treatment of  
205 lung cancer. *Ann Thorac Surg.* 2014;98(5):1830-2.  
206 33. Yang MH, Chuang H, Jung SM, Van YH, Lo FS. Pituitary apoplexy due to prolactinoma in a  
207 Taiwanese boy: patient report and review of the literature. *J Pediatr Endocrinol Metab.*  
208 2003;16(9):1301-5.  
209 34. Nakahara K, Oka H, Utsuki S, Iida H, Kurita M, Mochizuki T, et al. Pituitary apoplexy manifesting  
210 as diffuse subarachnoid hemorrhage. *Neurol Med Chir (Tokyo).* 2006;46(12):594-7.  
211 35. Kurisu K, Kawabori M, Niiya Y, Ohta Y, Mabuchi S, Houkin K. Pituitary apoplexy manifesting as  
212 massive intracerebral hemorrhage. Case report. *Neurol Med Chir (Tokyo).* 2012;52(8):587-90.  
213 36. Gruber A, Clayton J, Kumar S, Robertson I, Howlett TA, Mansell P. Pituitary apoplexy:  
214 retrospective review of 30 patients--is surgical intervention always necessary? *Br J Neurosurg.*  
215 2006;20(6):379-85.  
216  
217 37 CROWLEY HASAJN. Hydrocephalus complicating pituitary adenoma. *Journal ofNeurology,*  
218 *Neurosurgery, and Psychiatry* 1973, ;36, :1063-8.  
219 38 Danfeng Zhang JC, Zhenxing Li, Junyu Wang, Kaiwei Han and Lijun Hou Clinical features and  
220 management of nonfunctioning giant pituitary adenomas causing hydrocephalus. *Oncotarget,* .  
221 2018,; Vol. 9, ( . 20):15409-17.  
222